Dabogratinib (TYRA-300) 60mg Clinical Trials (2026): 5 Studies for FGFR3 Gene Alteration & FGFR3 Gene Mutation
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 Dabogratinib (TYRA-300) 60mg clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including FGFR3 Gene Alteration & FGFR3 Gene Mutation) and 782 total planned enrollment. 3 Dabogratinib (TYRA-300) 60mg clinical trials are actively recruiting at 51 U.S. sites across 20 states. Most recent activity: NCT07265947 (Nov 2030).
Where to Participate: All Dabogratinib (TYRA-300) 60mg Trial Sites in the U.S. (51 sites across 20 states)
Every actively recruiting Dabogratinib (TYRA-300) 60mgtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Urology Centers of Alabama | Homewood35209 | NCT06995677 | Map |
| AR | Arkansas Urology | Little Rock72211 | NCT06995677 | Map |
| CA | Tri Valley Urology - Murrieta | Murrieta92562 | NCT06995677 | Map |
| CA | Om Research LLC | San Diego92123 | NCT06995677 | Map |
| CA | Lundquist Institute for Biomedical Innovation | Torrance90502 | NCT06842355 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT06842355 | Map |
| DE | Nemours Alfred I duPont Hospital for Children | Wilmington19803 | NCT06842355 | Map |
| IL | Associated Urological Specialists | Chicago Ridge60415 | NCT06995677 | Map |
| IL | Duly Health and Care | Lisle60532 | NCT06995677 | Map |
| IL | Duly Health and Care Chicago | Lisle60532 | NCT07265947 | Map |
| IN | Urology of Indiana | Greenwood46143 | NCT06995677 | Map |
| IN | Urology of Indiana, LLC | Greenwood46143 | NCT07265947 | Map |
| IN | First Urology | Jeffersonville47130 | NCT06995677 | Map |
| IN | First Urology | Jeffersonville47130 | NCT07265947 | Map |
| KS | University of Kansas Medical Center (KUMC) | Kansas City66160 | NCT06995677 | Map |
| MD | Johns Hopkins University | Baltimore21205 | NCT06995677 | Map |
| MD | Johns Hopkins University School of Medicine | Baltimore21205 | NCT06842355 | Map |
| MD | Uncommon Cures | Chevy Chase20815 | NCT06842355 | Map |
| MA | Greater Boston Urology | Plymouth02360 | NCT06995677 | Map |
| MA | Greater Boston Urology - Plymouth Care Center | Plymouth02360 | NCT07265947 | Map |
| MO | University of Missouri | Columbia65201 | NCT06842355 | Map |
| MO | Washington University | St Louis63130 | NCT06842355 | Map |
| NJ | Atlantic Health System | Morristown07960 | NCT06995677 | Map |
| NJ | New Jersey Urology, LLC (Summit Health - Washington Township) | Voorhees Township08043 | NCT06995677 | Map |
| NY | Albany Medical College | Albany12208-3412 | NCT07265947 | Map |
| NY | Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers | New York10065 | NCT06995677 | Map |
| NY | Associated Medical Professionals of NY | Syracuse13210 | NCT06995677 | Map |
| NY | Associated Medical Professionals of NY, PLLC | Syracuse13210 | NCT07265947 | Map |
| NY | The Bronx Veterans Medical Research Foundation, Inc. | The Bronx10468 | NCT06995677 | Map |
| NC | Duke Cancer Institute | Durham27705 | NCT06995677 | Map |
| NC | Associate Urologist of North Carolina | Raleigh27612 | NCT06995677 | Map |
| OH | Cleveland Clinic | Cleveland44111 | NCT07265947 | Map |
| OH | The James at Brain and Spine Hospital (OSU) | Columbus43210 | NCT06995677 | Map |
| OH | Central Ohio Urology Group | Gahanna43230 | NCT07265947 | Map |
| OH | Oregon Urology Institute | Springfield97477 | NCT06995677 | Map |
| PA | MidLantic Urology | Bala-Cynwyd19004 | NCT06995677 | Map |
| PA | Keystone Urology Specialists | Lancaster17604 | NCT06995677 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT06995677 | Map |
| SC | Carolina Urologic Research Center | Myrtle Beach29572 | NCT06995677 | Map |
| SC | Lowcounty Urology Clinics, P.A. | North Charleston29406 | NCT06995677 | Map |
| TN | Conrad Pearson-Memphis | Germantown38138 | NCT06995677 | Map |
| TN | Urology Associates PC | Nashville37209 | NCT06995677 | Map |
| TN | Urology Associates, P C | Nashville37209-4035 | NCT07265947 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT06842355 | Map |
| TX | Urology Austin | Austin78759 | NCT06995677 | Map |
| TX | Children's Medical Center, Dallas | Dallas75235 | NCT06842355 | Map |
| TX | Baylor College of Medicine | Houston77030 | NCT06995677 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT07265947 | Map |
| TX | University of Texas Health Science Center Medical School at Houston | Houston77030 | NCT06842355 | Map |
| TX | Urology San Antonio | San Antonio78229 | NCT06995677 | Map |
| WI | University of Wisconsin-Madison | Madison53715 | NCT06842355 | Map |
Dabogratinib (TYRA-300) 60mg clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P1/P2 | 1 | 1 | |
| P2 | 3 | 3 |
Recruiting Dabogratinib (TYRA-300) 60mg clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07265947 | SURF303Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma | P2 | Low Grade Upper Tract Urothelial Carcinoma | 230 | Dec 2025 |
| NCT06842355 | A Study of TYRA-300 in Children With Achondroplasia: BEACH301 | P2 | Achondroplasia | 92 | Mar 2025 |
| NCT06995677 | SURF302Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | P2 | Low-grade NMIBC | 90 | Jun 2025 |
Dabogratinib (TYRA-300) 60mg clinical trials by indication
Low Grade Upper Tract Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07265947 | SURF303 | P2 | recruiting | Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma |
Low-grade NMIBC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06995677 | SURF302 | P2 | recruiting | Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer |
Achondroplasia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06842355 | — | P2 | recruiting | A Study of TYRA-300 in Children With Achondroplasia: BEACH301 |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06006702 | — | P1 | active not recruiting | A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants |
Locally Advanced Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05544552 | SURF301 | P1/P2 | active not recruiting | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations |
Dabogratinib (TYRA-300) 60mg pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SURF303 | NCT07265947 | P2 | recruiting | Low Grade Upper Tract Urothelial Carcinoma | 230 | — |
| SURF302 | NCT06995677 | P2 | recruiting | Low-grade NMIBC | 90 | — |
All Dabogratinib (TYRA-300) 60mg trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07265947 | SURF303 | Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma | P2 | recruiting | 230 | Tyra Biosciences, Inc | Dec 2025 |
| NCT06842355 | A Study of TYRA-300 in Children With Achondroplasia: BEACH301 | P2 | recruiting | 92 | Tyra Biosciences, Inc | Mar 2025 | |
| NCT06995677 | SURF302 | Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | P2 | recruiting | 90 | Tyra Biosciences, Inc | Jun 2025 |
| NCT05544552 | SURF301 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | P1/P2 | active not recruiting | 310 | Tyra Biosciences, Inc | Nov 2022 |
| NCT06006702 | A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants | P1 | active not recruiting | 60 | Tyra Biosciences, Inc | Oct 2023 |
Dabogratinib (TYRA-300) 60mg clinical trials: frequently asked questions
- How many Dabogratinib (TYRA-300) 60mg clinical trials are there?
- 5 Dabogratinib (TYRA-300) 60mg clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.
- Are Dabogratinib (TYRA-300) 60mg clinical trials recruiting in 2026?
- Yes — 3 Dabogratinib (TYRA-300) 60mg trials are actively recruiting in 2026, with 51 U.S. sites across 20 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Dabogratinib (TYRA-300) 60mg being studied for?
- Dabogratinib (TYRA-300) 60mg is being studied for FGFR3 Gene Alteration, FGFR3 Gene Mutation, Advanced Urothelial Carcinoma, Bladder Cancer, FGFR Gene Alterations and 16 more. The trials are grouped by indication on this page.
- What phase is Dabogratinib (TYRA-300) 60mg in?
- Dabogratinib (TYRA-300) 60mg clinical trials span 3 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Dabogratinib (TYRA-300) 60mg clinical trials?
- The lead sponsor across the most Dabogratinib (TYRA-300) 60mg trials is Tyra Biosciences, Inc. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Dabogratinib (TYRA-300) 60mgas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: